BILL SUMMARY
2nd Session of the 57th Legislature

Bill No.:	**HB 3418**
Version:	**Proposed Committee Substitute**
Request Number:	**10874**
Author:	**McEntire**
Date:	**2/25/2020**
Impact:	**Please see previous summary of this measure**

Research Analysis

The PCS to HB 3418 exempts the distribution of dialysate or peritoneal dialysis devices used for treating end-stage renal disease (ESRD) from the Oklahoma Pharmacy Act. However, dispensing facilities must ensure that the products are FDA-approved, held by a licensed manufacturer, delivered in their original packaging, delivered pursuant to a prescription, and delivered directly to the patient or health care provider responsible for administering the dialysis therapy. Products do not need to be certified by a pharmacist prior to delivery.

Prepared By: Anna Rouw

Fiscal Analysis

The measure is currently under review and impact information will be completed.

Prepared By: Mark Tygret

Other Considerations

None.